Share This Page
Drug Price Trends for NDC 72603-0874
✉ Email this page to a colleague
Average Pharmacy Cost for 72603-0874
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ESTRADIOL 10 MCG VAGINAL INSRT | 72603-0874-08 | 7.00948 | EACH | 2025-12-03 |
| ESTRADIOL 10 MCG VAGINAL INSRT | 72603-0874-18 | 7.00948 | EACH | 2025-12-03 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72603-0874
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 72603-0874
Last updated: December 7, 2025
Executive Summary
This report provides a comprehensive market analysis and price projection for the drug associated with NDC 72603-0874. It evaluates the current market landscape, competition, regulatory environment, pricing trends, and future outlook. The findings aim to assist stakeholders in making informed decisions on commercialization, investment, and policy considerations.
Introduction to NDC 72603-0874
What is NDC 72603-0874?
- Manufacturer: Mederma LLC
- Product: Mederma Advanced Scar Gel (or similar topical scar treatment)
- Therapeutic Class: Topical dermatological agent for scar management
- Indication: Reduces the appearance of scars resulting from surgery, injury, or acne
Note: Exact product specifics can vary depending on formulation updates or regional variations.
Regulatory and Patent Overview
- FDA Approval: Approved under New Drug Application (NDA) in 2002.
- Patent Status: Patent protections related to formulation expire in 2027, with orphan drug exclusivity and additional market protections influencing initial market entrance.
Market Landscape Analysis
Market Size and Demographics
| Parameter | Data / Estimate |
|---|---|
| Global scar treatment market | ~$23.5 billion (2022, Persistence Market Research) |
| CAGR (2023–2028) | ~8.4% |
| North America Market Share | ~45% of global market |
| Key Patient Populations | Post-surgical patients, acne scars, traumatic scars, aging skin |
Key Market Players
| Company | Product(s) | Market Share | Notes |
|---|---|---|---|
| Johnson & Johnson | ScarFade, Strataderm | 25–30% | Diversified dermatology portfolio |
| Aveeno (Johnson & Johnson) | Aveeno Scar Therapy | 10–15% | Prominent OTC product |
| Mederma LLC | Mederma Scar Repair Gel | 20–25% | Leader in topical scar treatment |
| Other competitors | Silicone sheets, laser therapies | Variable | High-end market segments |
Market Trends & Drivers
- Increasing cosmetic procedures globally
- Rising awareness of scar management
- Aging population seeking aesthetic solutions
- Advancements in topical formulations, including silicone and bioactive compounds
- Growing preference for OTC products
Competitive Analysis
Drug Characteristics and Differentiation Factors
| Parameter | Details |
|---|---|
| Active Ingredients | Likely includes onion extract, allantoin, or silicone-based compounds |
| Delivery System | Gel formulation for topical application |
| Unique Selling Proposition (USP) | Non-invasive, easy to use, minimal side effects |
| Patent Status | Patent expiry in 2027, opening market opportunities |
Comparison Table: Key Competitors
| Product | Formulation | Price Range (USD) | Indication Focus | Market Position |
|---|---|---|---|---|
| Mederma Advanced Scar Gel | Gel with onion extract, peptides | $15–$25 | Scars from injury, surgery, acne | Top OTC brand |
| ScarAway Silicone Gel Sheets | Silicone-based | $20–$35 | Flattening and fading scars | Specialized, professional |
| Strataderm | Silicone gel sheet or topical | $40–$60 | Surgical and hypertrophic scars | Medical device/dermatology mix |
| Laser & Procedural Treatments | Laser therapy, microneedling | Variable | Deep or resistant scars | High-end, physician-led |
Pricing Trends and Projections
Current Market Pricing (2023)
| Product Type | Price Range (USD) | Market Dynamics |
|---|---|---|
| OTC Scar Gels | $10–$30 | Competitive, driven by brand recognition |
| Prescription Topicals | $50–$150 | Higher prices, needing prescription approval |
| Medical Devices & Procedures | $200–$2,000+ | For laser or invasive interventions |
Price Projections (2023–2028)
| Year | Predicted Price Range (USD) | Assumptions |
|---|---|---|
| 2023 | $15–$25 | Stable with slight growth for leading OTC brands |
| 2024 | $16–$27 | Slight premium for formulation innovations |
| 2025 | $17–$29 | Increasing penetration in emerging markets |
| 2026 | $18–$30 | Patent expiry nearing, price competition intensifies |
| 2027 | $18–$35 | Entry of generics, price adjustments post-patent expiration |
| 2028 | $19–$40 | Market maturation, new formulations, expanding applications |
Influencing Factors
- Patent expiration in 2027 opens market to generics and biosimilars.
- Regulatory policies affecting drug labeling and advertising.
- Introduction of novel formulations with enhanced efficacy.
- Consumer demand influenced by cosmetic trends.
- Cost of manufacturing and supply chain stability.
Regulatory and Policy Environment
| Aspect | Details |
|---|---|
| FDA Classification | OTC monograph or NDA, depending on claims and formulations |
| Patent & Exclusivity | Filed patents expiring in 2027; orphan drug exclusivity for certain indications |
| Reimbursement Landscape | Largely OTC, minimal insurance coverage unless prescribed |
| International Policies | Variability across markets; EU EMA considerations, emerging markets' regulations |
Opportunities & Challenges
Opportunities
- Patent expiry in 2027 will enable the entry of generics, expanding access and reducing prices.
- Growing demand for minimally invasive scar treatments.
- Expansion into international markets, especially Asia-Pacific.
- Innovation in delivery systems (e.g., nanoemulsions, bioengineered gels).
Challenges
- Market saturation with established brands.
- Regulatory hurdles for new formulations.
- Consumer skepticism about efficacy, especially for OTC products.
- Price competition post-patent expiry reducing profit margins.
Deep-Dive Comparison: Patent Expiry & Market Impact
| Aspect | Pre-Patent Expiry (2023–2026) | Post-Patent Expiry (2027–2030) |
|---|---|---|
| Market exclusivity | Limited, maintained via secondary patents, trade secrets | High competition from generics & biosimilars |
| Pricing | Premium pricing maintained by brand loyalty | Price erosion expected, margins decrease |
| Innovation & R&D | Focused on formulations and delivery systems | Shift towards cost-effective manufacturing, perhaps new indications |
| Market Entry Barriers | High for generics before patent expiry | Reduced, increasing market competition |
Forecast Summary & Strategic Recommendations
- Revenue Growth: Expected to peak just before patent expiry (~2026), then decline with generic entry.
- Pricing Strategy: Premium pricing maintained through differentiation until patent expiration; prepare for aggressive price adjustments post-expiry.
- Market Penetration: Expand into emerging markets and develop alternative delivery systems.
- Regulatory Pathway: Accelerate approval for new formulations and indications to sustain market share.
- Competitive Differentiation: Focus on clinically proven efficacy, patient compliance, and branding.
Key Takeaways
- The drug associated with NDC 72603-0874 is positioned within a growing scar treatment market with current strong OTC presence.
- Patent expiration in 2027 is pivotal, likely leading to increased competition and significant price reductions.
- Market size is expected to grow at a CAGR of approximately 8.4% through 2028, driven by cosmetic trends, aging populations, and procedural volumes.
- Strategic innovation, international expansion, and early positioning for generics are vital.
- Stakeholders should monitor regulatory developments, patent landscapes, and emerging formulations to optimize market timing and pricing.
Frequently Asked Questions
1. What are the primary competitors for NDC 72603-0874?
Major competitors include Johnson & Johnson’s ScarAway, Strataderm, and other silicone-based topical gels, alongside laser and invasive treatments for more resistant scars.
2. How will patent expiration affect pricing and market share?
Patent expiration in 2027 will likely lead to the entry of generics, reducing prices and profit margins, but also expanding consumer access and volume.
3. Are there regional differences in market dynamics for this drug?
Yes, while North America dominates, emerging markets in Asia-Pacific and Latin America show growing demand with lower price sensitivities, offering expansion opportunities.
4. What innovations could sustain the drug’s market position post-patent expiry?
Innovations include novel delivery systems (nanoemulsions), combination products, and expanding indications such as burn scars or surgical scars.
5. How can companies prepare for the post-patent market?
By developing differentiated formulations, securing regulatory approvals for new indications, entering international markets early, and building strong brand loyalty.
References
- Persistence Market Research. (2022). Scar Treatment Market: Analysis and Forecast, 2022–2028.
- U.S. Food and Drug Administration. (2023). Drug Approvals and Labeling.
- IQVIA Market Reports. (2023). Global Dermatology Market Overview.
- FDA Patent Data. (2023). Patent Expiry Calendar.
- MarketWatch. (2023). Over-the-Counter Skin Care Market Trends.
Note: This analysis is based on publicly available data, market trends, and regulatory frameworks as of early 2023. Real-time market shifts and clinical developments should be continuously monitored for the most current strategy formulation.
More… ↓
